Sunday, November 27, 2011
Nationwide EHR System Getting Closer.
CNNMoney.com 
(11/21, Goldman) reports, "An electronic health records [EHR] network is becoming a reality, as the national attitude towards health IT is shifting towards acceptance. The ambitious goal of setting up a nationwide, interconnected, private and secure electronic health records system isn't yet a reality -- but we're getting closer." According to the Office of the National Coordinator for Health Information Technology (ONCHIT), "74% of hospitals have responded to surveys saying they are planning on investing in health information exchange services."
Exercise, Stents May Be Better Than Usual Care For Claudication.
MedPage Today 
(11/20, Kaiser) reported, "Compared with usual care for moderate to severe claudication, walking improved most with supervised exercise, but stenting won more quality-of-life points, researchers from the CLEVER trial found." Investigators reported that "the change from baseline in the peak walking time (the primary endpoint) at six months in the supervised exercise group was 4.6 minutes (P<0.001) and 2.5 minutes for those in the stenting group (P=0.02), compared with medical therapy alone." The research 
, published online in Circulation and presented at the American Heart Association meeting, indicated that "the difference in claudication onset time (a secondary endpoint) compared with usual care was 2.2 minutes for supervised exercise (P<0.003) and 2.9 minutes for stenting (P=0.006)."
Article Examines Pros, Cons Of Moderate Alcohol Consumption.
The Los Angeles Times 
(11/21, Adams) discusses the pros and cons of alcohol consumption, noting that evidence suggests that having heavy drinking "had long been known to raise the risk of breast cancer" by "increasing the amount of estrogen and related hormones." However, moderate alcohol intake is linked to a larger "drop in risk for heart disease" than the accompanying rise "in risk for breast cancer." Since women have "a higher lifetime risk of developing cardiovascular disease than breast cancer," it is difficult to make a "blanket recommendation for women who are trying to balance a breast cancer risk against cardiovascular benefits." Other benefits to moderate drinking may be "lower rates of diabetes, dementia, arthritis, enlarged prostate, osteoporosis, gall bladder disease, and even some cancers, such as those of the kidney and thyroid."
Dialysate flow rate and delivered Kt/Vurea for dialyzers with enhanced dialysate flow distribution.
Ward RA, Idoux JW, Hamdan H, et al. Dialysate flow rate and delivered Kt/Vurea for dialyzers with enhanced dialysate flow distribution. Clin J Am Soc Nephrol. 2011 Sep;6(9):2235-9. Epub 2011 Jul 28. (Original) PMID: 21799145
BACKGROUND AND OBJECTIVES: Previous in vitro and clinical studies showed that the urea mass transfer-area coefficient (K(o)A) increased with increasing dialysate flow rate. This observation led to increased dialysate flow rates in an attempt to maximize the delivered dose of dialysis (Kt/V(urea)). Recently, we showed that urea K(o)A was independent of dialysate flow rate in the range 500 to 800 ml/min for dialyzers incorporating features to enhance dialysate flow distribution, suggesting that increasing the dialysate flow rate with such dialyzers would not significantly increase delivered Kt/V(urea). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We performed a multi-center randomized clinical trial to compare delivered Kt/V(urea) at dialysate flow rates of 600 and 800 ml/min in 42 patients. All other aspects of the dialysis prescription, including treatment time, blood flow rate, and dialyzer, were kept constant for a given patient. Delivered single-pool and equilibrated Kt/V(urea) were calculated from pre- and postdialysis plasma urea concentrations, and ionic Kt/V was determined from serial measurements of ionic dialysance made throughout each treatment.
RESULTS: Delivered Kt/V(urea) differed between centers; however, the difference in Kt/V(urea) between dialysate flow rates of 800 and 600 ml/min was NS by any measure (95% confidence intervals of -0.064 to 0.024 for single-pool Kt/V(urea), -0.051 to 0.023 for equilibrated Kt/V(urea), and -0.029 to 0.099 for ionic Kt/V).
CONCLUSIONS: These data suggest that increasing the dialysate flow rate beyond 600 ml/min for these dialyzers offers no benefit in terms of delivered Kt/V(urea).
BACKGROUND AND OBJECTIVES: Previous in vitro and clinical studies showed that the urea mass transfer-area coefficient (K(o)A) increased with increasing dialysate flow rate. This observation led to increased dialysate flow rates in an attempt to maximize the delivered dose of dialysis (Kt/V(urea)). Recently, we showed that urea K(o)A was independent of dialysate flow rate in the range 500 to 800 ml/min for dialyzers incorporating features to enhance dialysate flow distribution, suggesting that increasing the dialysate flow rate with such dialyzers would not significantly increase delivered Kt/V(urea). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We performed a multi-center randomized clinical trial to compare delivered Kt/V(urea) at dialysate flow rates of 600 and 800 ml/min in 42 patients. All other aspects of the dialysis prescription, including treatment time, blood flow rate, and dialyzer, were kept constant for a given patient. Delivered single-pool and equilibrated Kt/V(urea) were calculated from pre- and postdialysis plasma urea concentrations, and ionic Kt/V was determined from serial measurements of ionic dialysance made throughout each treatment.
RESULTS: Delivered Kt/V(urea) differed between centers; however, the difference in Kt/V(urea) between dialysate flow rates of 800 and 600 ml/min was NS by any measure (95% confidence intervals of -0.064 to 0.024 for single-pool Kt/V(urea), -0.051 to 0.023 for equilibrated Kt/V(urea), and -0.029 to 0.099 for ionic Kt/V).
CONCLUSIONS: These data suggest that increasing the dialysate flow rate beyond 600 ml/min for these dialyzers offers no benefit in terms of delivered Kt/V(urea).
A1c targets for type 1 diabetes, dialysis patients discussed at nephrology meeting
PHILADEPHIA—Tight glucose control appears beneficial in preventing kidney function decline in newly diagnosed type 1 diabetics, but not so helpful for diabetics who already have kidney failure, according to data presented at the annual meeting of the American Society of Nephrology.
In a study that was also published online by the New England Journal of Medicine, researchers used follow-up data from the Diabetes Control and Complications Trial (DCCT) to determine the effect of intensive glucose control on glomerular filtration rate (GFR). Patients in the six-year trial were randomly assigned to either three or more insulin daily injections with an A1c target under 6.05% (actual average A1c in the group was 7.3%) or one or two daily injections to prevent symptoms of hyper- and hypoglycemia. Over a median follow-up of 22 years, half as many patients in the intensive group developed impaired GFR or end-stage renal disease (24 patients vs. 46 and 8 vs. 16, respectively). Although the applicability to type 2 diabetes is uncertain, the researchers concluded that the results reinforce current recommendations to target an A1c of 7% in patients with type 1 diabetes.
However, diabetic patients who were already on dialysis had the lowest risk of death if they had higher A1cs, according to two other large studies presented at the conference. In an observational study from 2001 to 2007 of more than 50,000 dialysis patients with diabetes, researchers from the University of California Los Angeles found that the lowest mortality levels were associated with an A1c between 7.0% and 7.9%, with increases in mortality both above and below this level. Serum glucose levels between 150 mg/dL and 175 mg/dL were associated with the lowest mortality, with increases in mortality at higher and lower glycemic levels. "High is bad, but very low is not good either," concluded study author Kamyar Kalantar-Zadeh, MD, PhD, FACP. "We need controlled trials to target certain ranges of A1c to verify these findings."
It wasn't a controlled trial, but the international Dialysis Outcomes and Practice Patterns Study (DOPPS) showed similar results in data presented at the conference. It included more than 8,000 hemodialysis patients and also found a U-shaped association between A1c and mortality, with the lowest risk associated with A1c levels of 7% to 8%. All-cause mortality risk appeared to be greatest at A1c levels of 9% or greater and less than 5%, and a trend toward higher mortality risk was seen at levels below 7%.
The authors of the latter two studies noted that current National Kidney Foundation guidelines recommend the same A1c targets for patients with kidney disease as other diabetics: below 7%. However, Katherine R. Tuttle, MD, FACP, who moderated the press conference at which the results were announced, said new guidelines have been drafted that include revised recommendations for glycemic targets in patients with kidney disease. The guidelines will be released soon for public review, she said.
In a study that was also published online by the New England Journal of Medicine, researchers used follow-up data from the Diabetes Control and Complications Trial (DCCT) to determine the effect of intensive glucose control on glomerular filtration rate (GFR). Patients in the six-year trial were randomly assigned to either three or more insulin daily injections with an A1c target under 6.05% (actual average A1c in the group was 7.3%) or one or two daily injections to prevent symptoms of hyper- and hypoglycemia. Over a median follow-up of 22 years, half as many patients in the intensive group developed impaired GFR or end-stage renal disease (24 patients vs. 46 and 8 vs. 16, respectively). Although the applicability to type 2 diabetes is uncertain, the researchers concluded that the results reinforce current recommendations to target an A1c of 7% in patients with type 1 diabetes.
However, diabetic patients who were already on dialysis had the lowest risk of death if they had higher A1cs, according to two other large studies presented at the conference. In an observational study from 2001 to 2007 of more than 50,000 dialysis patients with diabetes, researchers from the University of California Los Angeles found that the lowest mortality levels were associated with an A1c between 7.0% and 7.9%, with increases in mortality both above and below this level. Serum glucose levels between 150 mg/dL and 175 mg/dL were associated with the lowest mortality, with increases in mortality at higher and lower glycemic levels. "High is bad, but very low is not good either," concluded study author Kamyar Kalantar-Zadeh, MD, PhD, FACP. "We need controlled trials to target certain ranges of A1c to verify these findings."
It wasn't a controlled trial, but the international Dialysis Outcomes and Practice Patterns Study (DOPPS) showed similar results in data presented at the conference. It included more than 8,000 hemodialysis patients and also found a U-shaped association between A1c and mortality, with the lowest risk associated with A1c levels of 7% to 8%. All-cause mortality risk appeared to be greatest at A1c levels of 9% or greater and less than 5%, and a trend toward higher mortality risk was seen at levels below 7%.
The authors of the latter two studies noted that current National Kidney Foundation guidelines recommend the same A1c targets for patients with kidney disease as other diabetics: below 7%. However, Katherine R. Tuttle, MD, FACP, who moderated the press conference at which the results were announced, said new guidelines have been drafted that include revised recommendations for glycemic targets in patients with kidney disease. The guidelines will be released soon for public review, she said.
Want to stop smoking???
This is a useful website with information to help you improve your life and health by smoking cessation.
http://www.smokefree.gov/
http://www.smokefree.gov/
FDA Warns Fenofibric Acid (Fibricor or Trilipix) May Not Lower Heart Attack Risk.
MedPage Today 
(11/10, Gever) reports, "The FDA ordered on Wednesday that the label for fenofibric acid [Trilipix] be changed to indicate that the lipid-lowering drug has not been shown to reduce the risk of heart attack or stroke."
HeartWire
Subscribe to:
Posts (Atom)